Andere Sprachen Castle Biosciences, Inc.

Aktien

A2PNH3

US14843C1053

CSTL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
23,26 ^USD	-3,92 %		-4,55 %	+7,78 %

30.05.	Castle Biosciences, Inc. kündigt an, neue Daten zu seinen Tests DecisionDx-Melanoma und DecisionDx-UM auf der American Society of Clinical Oncology 2024 zu präsentieren	CI
29.05.	Castle Biosciences, Inc. gibt bekannt, dass eine neue Veröffentlichung zeigt, dass DecisionDx®-SCC Hochrisikopatienten mit Plattenepithelkarzinomen identifiziert, die wahrscheinlich von einer adjuvanten Strahlentherapie profitieren, und solche, bei denen ein Aufschub der Behandlung aufgrund des biologischen Risikos einer Metastasierung in Betracht gezogen werden kann	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	30.05.
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis	29.05.
Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing	08.05.
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival in Patients Diagnosed with UM	08.05.
Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024	02.05.
Castle Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024	02.05.
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	08.04.
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	04.04.
Castle Biosciences, Inc. Announces Board Changes	27.03.
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology	19.03.
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test	07.03.
Transcript : Castle Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28.02.
Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	28.02.
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Castle Biosciences Insider Sold Shares Worth $493,818, According to a Recent SEC Filing	07.02.
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii	14.01.
Castle Biosciences Insider Sold Shares Worth $475,585, According to a Recent SEC Filing	08.01.
Castle Biosciences Sees 53% Growth in Annual Revenue in 2023	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Castle Biosciences, Inc.

Aktien

A2PNH3

US14843C1053

CSTL

Andere Sprachen

Filter